Diagnos Stock Today

ADK Stock  CAD 0.33  0.01  3.13%   


9 of 100


Odds Of Distress

Less than 19

Diagnos is selling for under 0.33 as of the 18th of June 2024; that is 3.13 percent up since the beginning of the trading day. The stock's lowest day price was 0.32. Diagnos has less than a 19 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Diagnos are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of May 2024 and ending today, the 18th of June 2024. Click here to learn more.
Business Domain
Health Care Equipment & Services
Health Care
DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. The company was founded in 1998 and is headquartered in Brossard, Canada. DIAGNOS INC operates under Health Information Services classification in Canada and is traded on TSX Venture Exchange.. The company has 81.28 M outstanding shares of which 34.6 K shares are presently shorted by private and institutional investors with about 0.02 days to cover all short positions. More on Diagnos

Moving against Diagnos Stock

  0.56KDA KDA GroupPairCorr

Diagnos Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Diagnos' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Diagnos or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEOAndre Larente
Business ConcentrationHealth Care Technology, Health Care Equipment & Services, Health Care, Health Care, Health Care Technology, Health Information Services, Technology (View all Sectors)
Diagnos' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Diagnos' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Diagnos can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Diagnos' financial leverage. It provides some insight into what part of Diagnos' total assets is financed by creditors.
Diagnos cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. Diagnos has accumulated 168.89 K in total debt with debt to equity ratio (D/E) of 2.12, implying the company greatly relies on financing operations through barrowing. Diagnos has a current ratio of 1.17, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Diagnos until it has trouble settling it off, either with new capital or with free cash flow. So, Diagnos' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Diagnos sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Diagnos to invest in growth at high rates of return. When we think about Diagnos' use of debt, we should always consider it together with cash and equity.

Net Income

(2.34 Million)
Diagnos (ADK) is traded on TSX Venture Exchange in Canada and employs 5 people. Diagnos is listed under Health Care Technology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 27.63 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Diagnos's market, we take the total number of its shares issued and multiply it by Diagnos's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Diagnos classifies itself under Health Care Technology sector and is part of Health Care industry. The entity has 81.28 M outstanding shares of which 34.6 K shares are presently shorted by private and institutional investors with about 0.02 days to cover all short positions. Diagnos has accumulated about 97.5 K in cash with (1.88 M) of positive cash flow from operations.
Check Diagnos Probability Of Bankruptcy
Ownership Allocation
Diagnos retains a total of 81.28 Million outstanding shares. Diagnos shows 14.21 percent of its outstanding shares held by insiders and 0.01 percent owned by other corporate entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Diagnos Ownership Details

Diagnos Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Diagnos market risk premium is the additional return an investor will receive from holding Diagnos long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Diagnos. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Diagnos' alpha and beta are two of the key measurements used to evaluate Diagnos' performance over the market, the standard measures of volatility play an important role as well.

Diagnos Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in Diagnos without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Balance Of Power Now


Balance Of Power

Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
All  Next Launch Module

Diagnos Corporate Executives

Elected by the shareholders, the Diagnos' board of directors comprises two types of representatives: Diagnos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Diagnos. The board's role is to monitor Diagnos' management team and ensure that shareholders' interests are well served. Diagnos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Diagnos' outside directors are responsible for providing unbiased perspectives on the board's policies.

Additional Tools for Diagnos Stock Analysis

When running Diagnos' price analysis, check to measure Diagnos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diagnos is operating at the current time. Most of Diagnos' value examination focuses on studying past and present price action to predict the probability of Diagnos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diagnos' price. Additionally, you may evaluate how the addition of Diagnos to your portfolios can decrease your overall portfolio volatility.